Eric Coldwell
Stock Analyst at Baird
(3.75)
# 704
Out of 5,147 analysts
166
Total ratings
61.54%
Success rate
4.41%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $10.72 | +49.25% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $289.12 | +12.76% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $47.51 | +1.03% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $987.37 | -6.11% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $178.49 | +11.49% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $178.81 | +44.29% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $108.14 | +107.14% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $211.91 | -8.45% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $229.23 | -11.44% | 13 | Aug 13, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $451.76 | +8.46% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $9.15 | +74.86% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $65.72 | -31.53% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $79.90 | -17.40% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.83 | +5,442.17% | 4 | Nov 10, 2017 |
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $10.72
Upside: +49.25%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $289.12
Upside: +12.76%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $47.51
Upside: +1.03%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $987.37
Upside: -6.11%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $178.49
Upside: +11.49%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $178.81
Upside: +44.29%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $108.14
Upside: +107.14%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $211.91
Upside: -8.45%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $229.23
Upside: -11.44%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $451.76
Upside: +8.46%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $9.15
Upside: +74.86%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $65.72
Upside: -31.53%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $79.90
Upside: -17.40%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.83
Upside: +5,442.17%